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Reduced expression of deleted colorectal carcinoma
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Summary Using a bacterial fusion protein, a deleted colorectal carcinoma (DCC)-specific monoclonal antibody (MAb) 127-22 was
established. Although MAb 127-22 reacted with almost all normal tissues, it did not react or only weakly reacted with many cancer cell lines,
including colonic cancer lines, in flow cytometry. In Western immunoblots, the MAb reacted with a single 190-kDa molecule in a myeloma line
Ara-10 extract. This component was scarcely detected in colonic cancer cell lines. Immunoblots of samples from 25 pairs of colonic cancers
and adjacent normal tissues and from five adenoma tissues revealed that all normal colonic and adenoma tissues significantly expressed the
DCC protein, whereas colonic cancer tissues showed poor expression. These results indicate not only deletion of and lowered mRNA
expression ofthe DCCgene, but also marked reduction of DCC protein occurred in colonic cancertissues. In addition, colonic cancerpatients
with liver metastasis expressed significantly lower levels of DCC than those without, suggesting the prognostic value of DCC expression.
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The development of human cancer has been proposed to be a
multistep process (Nowell, 1986). Vogelstein et al (1988) showed
that colonic tumorigenesis provides the systematic course to the
multistep hypothesis at the molecular level. Several genes have
been identified that alter during tumour progression. Frequent and
consistent loss ofheterozygosity (LOH) of specific chromosomes
inhuman cancers has been associated withthe presence oftumour-
suppressor genes (Friend et al, 1986; Baker et al, 1989). In partic-
ular, the long arm ofchromosome 18 has been shown to be lost in
about 75% ofcolonic cancers (Vogelstein et al, 1988).
The tumour-suppressor gene DCC (deleted in colorectal carci-
noma), located on the long arm ofchromosome 18, encodes a cell-
surface protein containing homology with N-CAM (Fearon et al,
1990). There have been many reports on the loss ofheterozygosity
at the DCC gene locus in human colon cancers (Kem et al, 1989;
Kikuchi-Yanoshita et al, 1992; Itoh et al, 1993; Turley et al, 1995;
Thiagalingam et al, 1996), suggesting that DCC might be a
tumour-suppressor gene. Some reports also claim marked reduc-
tion of the gene expression in colon cancers based on the results
of reverse transcription polymerase chain reaction (RT-PCR).
However, only afew studies have beenperformed on the alteration
ofDCC protein in colon cancercells compared with that in normal
cells (Hedrick et al, 1992, 1994; Shibata et al, 1996).
In the present study, we generated aDCC-specific mouse mono-
clonal antibody (MAb) and analysed the expression levels ofDCC
proteins in various normal tissues, cancer cell lines and benign
and malignant colonic tumours. Here, we demonstrate dramatic
decreases of DCC protein as well as its mRNA in colon cancer
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tissues. Furthermore, we also investigated the clinical significance
ofthe reduction ofDCC expression in the diagnosis and treatment
ofcolorectal cancer patients.
MATERIALS AND METHODS
RT-PCR
Total RNA was extracted from ARA 10 (myeloma) using
guanidinium thiocyanate (Chomczynski and Sacchi, 1987). Single-
strand cDNA prepared from 3 gg of total RNA using Moloney
murine leukaemia virus reverse transcriptase (GIBCO-BRL,
Bethesda, MD, USA) with an oligo(dT)14 primer was used as the
template for the polymerase chain reaction (PCR). The primers for
PCR to amplify theDCC gene-codingregion were as follows: the 5'
primer DCC-AX encompassed positions 208-224 of the published
human DCC sequence (Fearon et al, 1990), 5'-GGGGATCCC-
CAGTGATCAAGTGGAA-3' (contained a BamHI site); the 3'
primer DCC-BX encompassed positions 416-432, 5'-GGGAATT
CTGAAAGGAACCTCAGTG-3' (contained an EcoRl site)
(Fearon et al, 1990). These primers and an oligo(dT)14 primer were
constructed using a 380B DNA synthesizer (Applied Biosystems,
Tokyo, Japan). Thirty cycles of denaturation (94°C, 1 min),
annealing (50°C, 1.5 min) and extension (72°C, 1 min) were carried
out in a thermal cycler (Program Temp Control System PC-700,
Astec, Fukuoka, Japan). Ten microlitres of the PCR products were
resolved by electrophoresis in polyacrylamide (12%) gels.
Construction of plasmid pBSK-DCC and DNA
sequencing
The PCR products were digested with BamHI and EcoRI, sepa-
ratedbypolyacrylamide gel, purified by electroelution, and cloned
into theBamHI andEcoRI sites ofpBluescript II SK- (Stratagene).
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DNA was sequenced using the Sequenase version 2.0 kit (United
States Biochemical, Cleveland, OH, USA) with [a-32P]dCTP.
Construction of plasmid pGEX-DCC used to express
DCC in E. coil
Plasmid pGEX-DCC was constructed to express DCC proteins
fused with a 26-kDa glutathione S-transferase (GST) in E. coli,
using theBamHI-EcoRI fragments (225 basepairs) ofpBSK-DCC.
After digestion, the fragment was subcloned into the BamHI and
EcoRI sites ofpGEX-2T (Pharmacia, Uppsala, Sweden). DH5a E.
coli transformed with pGEX-2T vector was used as control.
Preparation and affinity purification of bacterial
extracts
This is performed principally as described by Smith and Johnson
(1988). In brief, overnight bacterial cultures were diluted 1:10 (to
400 ml) in fresh medium and incubated for 2 h. Isopropyl-o-D-
thiogalactopyranoside was added to a final concentration of
0.1 mm and incubated for a further 4 h. The cells were then
pelleted, resuspended in 10 ml of MTPBS (150 mm sodium chlo-
ride, 16 mm disodium hydrogen phosphate, 4 mm sodium dihy-
drogen phosphate, pH 7.3) containing 1% Triton X-100. The cells
were lysed on ice by mild sonication, then centrifuged at 10000g
for 5 min at 4°C. The supernatants were loaded onto a column
containing glutathione sepharose 4B (Pharmacia). After washing
the column twice with five bed volumes of MTPBS, the bound
fractions were eluted with about four bed volumes of elution
buffer containing 5 mm reduced glutathione (KOHJIN, Tokyo,
Japan) in 50 mM Tris-HCl, pH 8.0. The purity ofthe proteins was
confirmed by sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) by staining with Coomassie blue. The
protein concentration was estimated from the absorbance at
280 nm (1 A280 = 0.5 mg ml-1).
Monoclonal antibody
A mouse was immunized s.c. three times with DCC fusion protein
at 2-week intervals: the first time with 50 jg of protein with
complete Freund's adjuvant, the second with 100 jg of protein
with incomplete Freund's adjuvant and the third with 100 jg of
protein alone. Spleen cells were obtained from the mouse and
fused with the murine myeloma cell line NS-1. The hybridoma
culture supematants were assayed for reactivity with the DCC
protein using an enzyme-linked immunosorbent assay and
immunoblotting. Positive cultures were clonedby limiting dilution
three times to obtain the MAb DCC127-22, which is specifically
reactive with the DCC protein.
Cells
The cell lines were maintained in RPMI 1640containing 10% fetal
bovine serum (leukaemia lines) or in Dulbecco's modified Eagle
medium containing 7.5% fetal bovine serum (monolayercells) and
cultured in a carbon dioxide incubator at 37°C. The derivation of
the cell lines was as follows - human colorectal cell lines: CCK-
81, CoCM-1, RCM-1, WiDr and VMRC-MELG (melanoma in the
colon); stomach cell lines: AZ-521, MKN-1 and SCH; and B-cell
lines: BALL-1, CCRF-SB, HS-Sultan, IM9 and Ramos (obtained
from the Japanese Cancer Research Resources Bank). Other cell
lines were obtained as described in Yamashiro et al (1993).
Flow cytometry
Flow cytometry was performed as described previously
(Yamashiro et al, 1993). Briefly, the cells were incubated with
appropriately diluted MAb for 45 min on ice. After two washes
with phosphate-buffered saline (PBS), the cells were incubated
with 100g1 of 100-fold-diluted fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG (Cappel, West Chester, PA, USA) for
30 min on ice. After two washes, the cells were examined using a
FACScan (Becton-Dickinson, Mountain View, CA, USA).
Western blot
Cells were lysed in 0.01 M Tris buffer, pH 7.3, containing 0.15 M
sodium chloride, 0.01 M magnesium chloride, 0.5% NP-40, 1 mm
phenylmethylsulphonyl fluoride (PMSF) (Sigma, St Louis, MO,
USA) and 20 U ml-' of aprotinin (Bayer, Leverkusen, Germany).
Usually, 100 jig ofprotein determined using the Bradford method
(Bradford, 1976) was resolved by SDS-PAGE according to
Laemmli (1970) and transferred to a PVDF membrane
(Immobilon, 0.22-,um pore size) (Nihon Millipore Kogyo KK,
Tokyo, Japan) for 4.5 h at 70 V in blotting buffer consisting of
0.025M Tris, 0.192M glycine and 20% methanol. The protein
blots were incubated in PBS with 5% non-fat dry milk
(Yukijirushi, Sapporo, Japan) and 0.02% sodium azide at 4°C
overnight. The membranes were incubated with MAb
DCC127-22 at room temperature for 1 h and washed with T-PBS
(PBS containing 0.05% Tween-20) three times. Proteins were
immunodetected using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) according to the manufac-
turer's instructions. The proteins were visualized using a Konica
immunostaining HRP kit (Konica, Tokyo, Japan). The intensity of
the bands was measured by a densitometer (Yamashiro et al,
1995), and the ratio ofthe DCC bands in cancer tissues to those of
the adjacent normal mucosa was calculated. Data were presented
as the mean ± standard deviation. Statistical analysis was
performed by the chi-square test. Differences were taken as being
significant when the P-value was less than 0.05.
Tumour specimens
Primary tumour samples and normal tissues were obtained from
surgical resection specimens from patients with colon cancer or
endoscopic polypectomy specimens of adenoma at the First
Department of Surgery, Fukui Medical School, Fukui, Japan. All
samples had been snap frozen in liquid nitrogen immediately after
surgical excision and stored at -80°C until use. Of the primary
carcinomas, eight were well differentiated, 13 were moderately
differentiated, two were mucinous and one case was a poorly
differentiated adenocarcinoma. These studies have been carried out
with approval ofthe ethical committee ofFukui Medical School.
Immunohistochemical staining of tissues
Paraffin-embedded blocks of acetone, methanol and xylene-fixed
(AMeX method; Sato et al, 1986) tissues were sliced into 4-jm
sections, deparaffinized and immersed in methanol containing 1%
hydrogen peroxide for 20 min to eliminate endogenous peroxidase
activity. Afterpreincubation with normal goat serum for 20 min at
room temperature, the sections were incubated with MAb
DCC127-22 (1 jig ml-') for 4 h at room temperature. They were
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Figure 1 Production of a GST-DCC protein in E. cofiand generation of a
MAb reactive with DCC. (A) Expression of the DCC fusion protein.
Coomassie blue staining of the soluble fusion protein purified from E. coii
transformed with pGEX-DCC (lane 1), and purified GST produced in E. coli
transformed with pGEX-2T alone (lane 2). (B) Western blot of the purified
DCC fusion protein (lane 1) and GST protein (lane 2) as in A with MAb
127-22. Bands were detected by ABC kit as described in Materials and
methods
ARAl0
29 DLD-1
Fluorescence intensity
Table 1 DCC expression in cell lines as determined by RT-PCR and flow
cytometry
Cell lines RT-PCRa FACSb
Myeloid
K562 - -
MEG-01 - -
NKM-1 - -
T-ALL
CCRF-CEM - -
Jurkat - -
Molt4 - -
B-ALL
Raji
Daudi
ARA-10
GM1311
RPM18226
Null-ALL
NALM-1
NALM-6
++
++
++
++
Colon carcinoma
HT29
DLD-1
LoVo
RPM18226 WiDr
SW480
SW1083
Gastric carcinoma
AZ521
NUGC4
MKN1
MKN45
Pancreatic carcinoma
Capan-1
Lung carcinoma
Calu-1
Melanoma
SK-MEL-23
Neuroblastoma
IMR-32 + +
alntensities were scored based on the ethidium bromide staining. bintensities
were classified as follows: -, 0-20%; +, 20-40%; ++, 40-60%; +++, >60%.
Figure 2 Cell-surface reactivity of MAb 127-22 with various cell lines.
Results of flow cytometry of ARA10 (myeloma), RPM18226 (myeloma), HT29
(colon cancer) and DLD-1 (colon cancer) are shown. The detection reagent
was FITC-conjugated goat anti-mouse IgG (H and L)
then washed with PBS and incubated with biotinylated goat anti-
mouse IgG antibody (Vector) at room temperature for 30 min,
followed by streptavidin-biotin peroxidase (Vector) for 30 min.
The sections were then incubated in PBS containing 0.03%
diaminobenzidine and 0.01% hydrogen peroxide. Finally, the
slides were lightly counterstained with 1% methyl green.
RESULTS
Production of a GST-DCC protein in E. coiland
generation of a MAb reactive with DCC
The entire DCC gene-coding region was translated as a fusion
protein with a 26-kDa GST. The partly soluble fusion proteins
purified by affinity chromatography using glutathione sepharose 4B
migrated as a few bands at 40 kDa in SDS-PAGE (Figure IA).
Using these fusion proteins, a MAb DCC127-22 was generated that
specifically reacted with DCC proteins but not with GST as shown
in Figure lB. The Ig subclass ofMAb DCC127-22 was IgG1.
Cell-surface expression of DCC recognized by MAb
DCC127-22
We examined whether MAb DCC127-22 was reactive with cell-
surface molecules on various human cell lines by means of flow
cytometry. As shown in Figure 2, MAb DCC127-22 was reactive
with ARAlO and RPM18226. It was not reactive with HT29 and
DLD-1. A summary ofthe flow cytometric analysis ofcell lines is
shown in Table 1. Many haematopoietic and non-haematopoietic
cell lines examined were not reactive with MAb DCC127-22,
except some leukaemia lines, suggesting that the DCC epitope is
rarely expressed in a wide range of cancer cells.
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Figure 3 Western blot of several human cell lines with MAb 127-22. Cell
lines were as described in Materials and methods. The same amount of cell
lysate was loaded in each lane, as determined using the Bradford method
(Bradford, 1976). The lysates were resolved on 12% PAGE and blotted onto
a PVDF membrane. Proteins were stained with MAb 127-22 as described in
Materials and methods
B
Figure 4 Immunohistochemical staining of normal colonic mucosa and
colonic cancer. DCC proteins were stained with MAb 127-22 in sections of
colonic cancer containing normal mucosa as described in Materials and
methods. A border of colonic cancer (right side) and normal mucosa (left
side) is shown (A) (xlOO). B shows a high magnification of A (x200). Note
the distinct staining patterns between cancer and normal tissues
Adenoma Cancer
3 4 5 dL 2 3
-190 kDa
Figure 5 Western blots of NP-40 extracts from colonic adenomas, several
primary colonic cancers and adjacent normal colonic tissues with MAb
127-22. Arrow, DCC epitope-positive protein. The same amount of cell lysate
was loaded in each lane, based upon the protein concentration determined
using the Bradford method (Bradford, 1976). The lysates were resolved on
10% SDS-PAGE. Numbers 1-5 represent adenoma samples from five
patients. Numbers 1-4, four primary colonic cancers (T) and adjacent normal
colonic tissues (N). The reaction with MAb 127-22 proceeded as described
in the legend to Figure 3
0.8
0.6
0.4
0.2
.0
30
3'9
*0
Adenoma Cancer
(n=5) (n=25)
Figure 6 The ratio of intensities of DCC bands (tumour/normal) in colonic
adenomas and colonic cancer samples. The numbers represent the average
value ± s.d. of the ratio of DCC bands in the individual groups. The P-value
for the difference between DCC levels in colonic adenomas and colonic
cancer samples is below 0.05
Western blots with various cell lines
DCC expression in cancer cell lines was analysed by immuno-
blotting using MAb 127-22. A representative example is shown in
Figure 3. A specific band of 190 kDa was observed in ARA10 and
RPMI-8226. Colorectal and stomach cancer lines were negative.
mRNA expression of DCC in haematopoietic and colon
cancer cell lines
Theexpression ofDCCmRNA was analysedby RT-PCR followed
by ethidium bromide staining. There was a major amplified band
at 225 bp in AralO and IMR32, but not in human colonic cancer
cell lines (data not shown). A summary of the flow cytometric
analysis and RT-PCR is shown in Table 1. Consequently, the
expression of a 190-kDa band detected in immunoblot corre-
sponded well with mRNA expression of DCC gene as measured
by RT-PCR.
Immunohistochemistry of normal human tissues and
colonic cancers using MAb 127-22
The expression of DCC in normal human tissues was analysed
using immunohistostaining. All tissues expressed some levels of
DCC, although there were some differences in the intensities of
the staining. Colonic cancer tissue and corresponding normal
tissue were then examined using immunohistochemistry. For
normal tissue, the staining was intense, mainly on the apical aspect
of the cells, while colonic cancer tissue was not stained (Figure
4A). Figure 4B shows a high magnification ofthe border between
colon cancer tissue and normal tissue and demonstrates a distinct
staining pattern.
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Figure 7 The ratio of DCC bands (cancer/normal) in primary colonic tissues
with (+) and without (-) liver metastasis. The numbers represent the average
values ± s.d. of the ratio of DCC bands in the individual groups. The P-value
for the difference between DCC levels in the two groups was calculated
using the chi-square test and was below 0.05
Decreased expression of protein in colonic cancer
The expression of DCC protein in colonic cancers, adjacent
normal mucosae and adenomas was analysed by immunoblotting
using MAb 127-22. Representative examples are shown in Figure
5. Prominent 190-kDa bands ofDCC were observed in the extracts
from normal colonic mucosae and adenomas, whereas bands were
undetectable in the extracts from corresponding colonic cancers.
In all samples examined, DCC protein was more prominently
expressed in the adjacent normal colonic mucosae and adenoma
tissues than in the colonic cancer tissues. Figure 6 is a summary of
Western immunoblots showing the ratio of DCC bands (tumour/
normal) in adenoma and colon cancer samples. Thus, development
of cancers appears to result in the marked reduction of DCC
protein, as benign adenomas contained levels equivalent to those
in normal tissues.
Liver metastasis and DCC expression
Among 25 colon cancer tissues, 15 samples with no liver metas-
tasis showed significantly higher levels of DCC than ten samples
with liver metastasis as shown in Figure 7. These results indicate
the possible use of DCC as a prognostic factor in colon cancer
patients.
DISCUSSION
Since DCC was discovered by Vogelstein et al in 1990 (Fearon et
al, 1990), there have been many reports describing the high
frequency of LOH at the DCC locus in the colon cancer tissues
(Fearon et al, 1994; lacopetta et al, 1994; lino et al, 1994), and in
many other cancers (Hohne et al, 1992; Miyake et al, 1994; Murty
et al, 1994; Kashiwaba et al, 1995; Cho et al, 1996). DCChas been
evaluated as a tumour-suppressor gene candidate on chromosome
18 in colorectal cancers (Thiagalingam et al, 1996). RT-PCR
approaches have also been used to show lower expression of the
DCC gene in colon cancer tissues compared with adjacent normal
colonic mucosae (Kikuchi-Yanoshita et al, 1992; Itoh et al, 1993;
lino et al, 1994). However, only a few reports on the DCC protein
levels in colon cancer and normal colonic tissues in individual
patients have been published. Protein analysis has been reported in
normal tissues (Turley et al, 1995), for leukaemia and MDS
(Inokuchi et al, 1996) and for brain tumours (Ekstrand et al, 1995).
In the present study, we have established a DCC-specific MAb by
using a GST-DCC fusion protein for immunization. This MAb
proved to be very useful in Western immunoblot, flow cytometry
and immunohistostaining. As expected, DCC protein was scarcely
detectable in human cancer cell lines, except for some
haematopoietic lines. Colon cancer tissues from patients were also
negative or they expressed at a very low level. On the other hand,
normal colonic tissues -and adenoma tissues showed almost equiv-
alent intensities of DCC bands in immunoblots. These results are
very similar to the immunohistochemical studies reported recently
by Shibata et al (1996). The fact that five adenomas showed equiv-
alent expression levels to normal tissues suggested that the reduc-
tion observed in carcinomas is a relatively late phenotypic event.
These results indicate that DCC may play an important role as a
tumour-suppressor gene, and down-regulation or defect of the
gene may trigger progression ofcolon cancers from adenomas.
The immunoblot results of DCC showed fairly broad variations
in the cancer/normal expression ratio between samples as shown in
Figures 6 and 7. This may be partly due to varying levels ofconta-
mination of non-tumour tissue present in each case. The data for
cancer cell lines in which DCC bands could be scarcely seen also
suggest this possibility.
Furthermore, it has been demonstrated that the inactivation of
the DCC gene orreduction ofDCCgene expression closely corre-
lates with cancer metastasis. Recent studies have indicated the
importance ofDCC alterations in liver metastasis (Itoh et al, 1993;
Ookawa et al, 1993; lino et al, 1994; Kato et al, 1996) or nodal
metastasis (Kataoka et al, 1995) ofcolorectal cancers. Our quanti-
tative data of DCC protein also indicate a reverse correlation
between DCC levels and frequency of liver metastasis in colon
cancers, suggesting its value as a prognostic marker. As the obser-
vation time after operation was not long enough, the prognosis of
each patient has notbeen examined. However, the results shown in
Figure 7 may be useful in identifying primary tumours likely to
have liver metastases. The study of a larger number of tumours is
also needed.
As for the biological function of DCC, no definite roles of the
molecule have been elucidated so far. As DCC has high homology
with N-CAM, one of the adhesion molecules abundantly
expressed in nervous tissues, it might play an important role in
cell-cell or cell-extracellular matrix interaction during develop-
ment or differentiation (Fearon et al, 1994). Some reports strongly
indicate that DCC is important for cell differentiation (Hedrick
et al, 1994), particularly in the differentiation of neuronal cells
(Laelor and Narayanan, 1992). Recently, Goyette has shown that
chromosome 18 restores TGF-3 responsiveness and reduces
tumorigenicity in the human colonic carcinoma cell line SW480. It
may be important to determine whether the DCCgene is sufficient
to restore responsiveness to TGF-1 and suppress tumorigenicity.
In fact, transformed epithelial cells have been reversed from the
malignant phenotype by the introduction of the DCC gene
(Klingelhutz et al, 1995). Further understanding of the biological
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functions ofDCC will provide more effective methods ofits appli-
cation for diagnostic and therapeutic purposes.
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